LGC acquires Rapid Genomics
Bolstering its position in the application of NGS for high-throughput genotyping market in AgBio
LGC has announced the acquisition of Rapid Genomics, a provider of mid- to high-density Next-Generation Sequencing (NGS) kits and services for genotyping in the agrigenomics market.
Rapid Genomics is a leading company in genotyping applications via Next-Generation Sequencing (NGS). Its Flex-Seq® Ex-L technology is provided to customers through kits and genotyping services, and allows high-throughput, cost-effective DNA analysis in plant, livestock and aquaculture genetics. This in turn enables development of more productive and resilient plants and animals, as well as food safety and animal health applications through the identification and screening of pathogens.
Mark Dearden, Managing Director, LGC, Biosearch Technologies, said, “We are excited to secure Rapid Genomics, which is an elegant fit with our core purpose of Science for a Safer World. This acquisition will enable future growth and development of our NGS high-throughput offerings in the agrigenomics space. Rapid Genomics is an excellent complement to our existing NGS and PCR genomics capabilities and we look forward to bringing the combined offering to our customers.”
Leandro Neves, CEO and President of Rapid Genomics, said, “We are honoured to join the LGC team. Our companies have worked together for several years with great synergy and shared vision. The access to LGC’s expertise in the field and broad technologies will have a multiplier effect on our ability to provide innovative solutions to our customers. We are excited to be part of LGC and leverage this opportunity to benefit our employees and customers.”
Founded in 2011 in Gainesville, Florida, USA, Rapid Genomics currently has 30 employees.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Biomarkers help predict prostate cancer progression
The fiber of our being

RAYDIAX secures €3.5 million in fresh capital to develop its therapy assistance computed tomography system in the fight against cancer
